Rapamycin inhibits the growth of glioblastoma

Research output: Contribution to journalArticle

Abstract

The molecular target of rapamycin (mTOR) is up-regulated in glioblastoma (GBM) and this is associated with the rate of cell growth, stem cell proliferation and disease relapse. Rapamycin is a powerful mTOR inhibitor and strong autophagy inducer. Previous studies analyzed the effects of rapamycin in GBM cell lines. However, to our knowledge, no experiment was carried out to evaluate the effects of rapamycin neither in primary cells derived from GBM patients nor in vivo in brain GBM xenograft. These data are critical to get a deeper insight into the effects of such adjuvant therapy in GBM patients. In the present study, various doses of rapamycin were tested in primary cell cultures from GBM patients. These effects were compared with that obtained by the same doses of rapamycin in GBM cell lines (U87Mg). The effects of rapamycin were also evaluated in vivo, in brain tumors developed from mouse xenografts. Rapamycin, starting at the dose of 10 nm inhibited cell growth both in U87Mg cell line and primary cell cultures derived from various GBM patients. When administered in vivo to brain xenografts in nude mice rapamycin almost doubled the survival time of mice and inhibited by more than 95% of tumor volume.

Original languageEnglish
Pages (from-to)37-51
Number of pages15
JournalBrain Research
Volume1495
DOIs
Publication statusPublished - Feb 7 2013

Fingerprint

Sirolimus
Glioblastoma
Growth
Heterografts
Primary Cell Culture
Cell Line
Autophagy
Brain
Tumor Burden
Nude Mice
Brain Neoplasms
Stem Cells
Cell Proliferation
Recurrence
Survival

Keywords

  • GBM brain xenografts
  • Glioblastoma
  • Human GBM primary cultures
  • mTOR
  • Rapamycin

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

@article{b01cd307f7cf490aa82f9cbc95ea0f09,
title = "Rapamycin inhibits the growth of glioblastoma",
abstract = "The molecular target of rapamycin (mTOR) is up-regulated in glioblastoma (GBM) and this is associated with the rate of cell growth, stem cell proliferation and disease relapse. Rapamycin is a powerful mTOR inhibitor and strong autophagy inducer. Previous studies analyzed the effects of rapamycin in GBM cell lines. However, to our knowledge, no experiment was carried out to evaluate the effects of rapamycin neither in primary cells derived from GBM patients nor in vivo in brain GBM xenograft. These data are critical to get a deeper insight into the effects of such adjuvant therapy in GBM patients. In the present study, various doses of rapamycin were tested in primary cell cultures from GBM patients. These effects were compared with that obtained by the same doses of rapamycin in GBM cell lines (U87Mg). The effects of rapamycin were also evaluated in vivo, in brain tumors developed from mouse xenografts. Rapamycin, starting at the dose of 10 nm inhibited cell growth both in U87Mg cell line and primary cell cultures derived from various GBM patients. When administered in vivo to brain xenografts in nude mice rapamycin almost doubled the survival time of mice and inhibited by more than 95{\%} of tumor volume.",
keywords = "GBM brain xenografts, Glioblastoma, Human GBM primary cultures, mTOR, Rapamycin",
author = "Antonietta Arcella and Francesca Biagioni and {Antonietta Oliva}, Maria and Domenico Bucci and Alessandro Frati and Vincenzo Esposito and Giampaolo Cantore and Felice Giangaspero and Francesco Fornai",
year = "2013",
month = "2",
day = "7",
doi = "10.1016/j.brainres.2012.11.044",
language = "English",
volume = "1495",
pages = "37--51",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Rapamycin inhibits the growth of glioblastoma

AU - Arcella, Antonietta

AU - Biagioni, Francesca

AU - Antonietta Oliva, Maria

AU - Bucci, Domenico

AU - Frati, Alessandro

AU - Esposito, Vincenzo

AU - Cantore, Giampaolo

AU - Giangaspero, Felice

AU - Fornai, Francesco

PY - 2013/2/7

Y1 - 2013/2/7

N2 - The molecular target of rapamycin (mTOR) is up-regulated in glioblastoma (GBM) and this is associated with the rate of cell growth, stem cell proliferation and disease relapse. Rapamycin is a powerful mTOR inhibitor and strong autophagy inducer. Previous studies analyzed the effects of rapamycin in GBM cell lines. However, to our knowledge, no experiment was carried out to evaluate the effects of rapamycin neither in primary cells derived from GBM patients nor in vivo in brain GBM xenograft. These data are critical to get a deeper insight into the effects of such adjuvant therapy in GBM patients. In the present study, various doses of rapamycin were tested in primary cell cultures from GBM patients. These effects were compared with that obtained by the same doses of rapamycin in GBM cell lines (U87Mg). The effects of rapamycin were also evaluated in vivo, in brain tumors developed from mouse xenografts. Rapamycin, starting at the dose of 10 nm inhibited cell growth both in U87Mg cell line and primary cell cultures derived from various GBM patients. When administered in vivo to brain xenografts in nude mice rapamycin almost doubled the survival time of mice and inhibited by more than 95% of tumor volume.

AB - The molecular target of rapamycin (mTOR) is up-regulated in glioblastoma (GBM) and this is associated with the rate of cell growth, stem cell proliferation and disease relapse. Rapamycin is a powerful mTOR inhibitor and strong autophagy inducer. Previous studies analyzed the effects of rapamycin in GBM cell lines. However, to our knowledge, no experiment was carried out to evaluate the effects of rapamycin neither in primary cells derived from GBM patients nor in vivo in brain GBM xenograft. These data are critical to get a deeper insight into the effects of such adjuvant therapy in GBM patients. In the present study, various doses of rapamycin were tested in primary cell cultures from GBM patients. These effects were compared with that obtained by the same doses of rapamycin in GBM cell lines (U87Mg). The effects of rapamycin were also evaluated in vivo, in brain tumors developed from mouse xenografts. Rapamycin, starting at the dose of 10 nm inhibited cell growth both in U87Mg cell line and primary cell cultures derived from various GBM patients. When administered in vivo to brain xenografts in nude mice rapamycin almost doubled the survival time of mice and inhibited by more than 95% of tumor volume.

KW - GBM brain xenografts

KW - Glioblastoma

KW - Human GBM primary cultures

KW - mTOR

KW - Rapamycin

UR - http://www.scopus.com/inward/record.url?scp=84872383987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872383987&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2012.11.044

DO - 10.1016/j.brainres.2012.11.044

M3 - Article

C2 - 23261661

AN - SCOPUS:84872383987

VL - 1495

SP - 37

EP - 51

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -